Ignite Creation Date:
2025-12-24 @ 7:02 PM
Ignite Modification Date:
2026-02-22 @ 7:04 AM
Study NCT ID:
NCT03829657
Status:
TERMINATED
Last Update Posted:
2023-01-20
First Post:
2019-01-10
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
Sponsor:
Theravance Biopharma
Organization:
Conditions & Keywords Data
Conditions:
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Symptomatic Neurogenic Orthostatic Hypotension | View |
| None | symptomatic nOH | View |
| None | multiple symptom atrophy | View |
| None | MSA | View |
| None | Parkinson's disease | View |
| None | PD | View |
| None | pure autonomic failure | View |
| None | PAF | View |
| None | orthostatic hypotension | View |
| None | OH | View |
| None | REDWOOD | View |
| None | ampreloxetine | View |
| None | low blood pressure | View |
| None | dizziness | View |
| None | fainting | View |
| None | blacking out | View |
| None | lightheadedness | View |
| None | norepinephrine | View |
| None | hypotension | View |
| None | Neurogenic Orthostatic Hypotension | View |
| None | nOH | View |
| None | 170 | View |
| None | 0170 | View |
| None | 145 | View |
| None | 0145 | View |
| None | TD-9855 | View |
| None | TD9855 | View |
| None | Parkinsonism | View |